Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2017 / Mar / Benchmarking Dry AMD
Research & Innovations Retina

Benchmarking Dry AMD

What does analysis of the last five years of dry AMD literature tell us about the priorities of the field and its major contributors?

By Roisin McGuigan 3/3/2017 1 min read

Share

Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries and the third-leading cause in developing countries. Dry AMD, unlike the neovascular, wet form, has no effective therapies available today – bad news, especially as it comprises about 85–90 percent of all AMD cases. Then again, a number of potentially disease-modifying therapies are currently under clinical evaluation, so this situation may change in the future.

In 2015, we benchmarked the PubMed-listed AMD literature as a whole (1), and we’ve also reviewed the entirety of the AMD trial data that’s available on clinicaltrials.gov (2). This month, we set out to specifically assess the dry AMD literature. To provide insight into the past and predictions for the future of the field, a series of metrics were applied to the last five years of published literature.

We asked:
  • Who has published the most?
  • Who has had the greatest impact?
  • What are the big topics being discussed?
  • Is this knowledge available online (for free or for a fee)?
PubMed was searched for dry AND “macular degeneration”, with results limited to the last five years, and the data were analyzed in Microsoft Excel 2013.

References

  1. M Hillen, “Benchmarking AMD”, The Ophthalmologist, 17, 38–40 (2015). Available at: http://top.txp.to/issues/0315/501/. Accessed January 23, 2017. M Hillen, R McGuigan, “AMD Clinical Trials”, The Ophthalmologist, 22, 38–40 (2015). Available at: http://top.txp.to/issues/0815/501/. Accessed January 23, 2017.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: